Post-earnings recap
Reported
Tue, Nov 25, 2025
EPS actual
$-0.01
EPS est.
$0.12
EPS surprise
-108.62%
1-day move
+5.72%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing on EPS, Arrowhead Pharmaceuticals saw a positive stock reaction, rising 5.72%. This increase may reflect investor confidence in the company's ongoing research and development efforts. Management's focus on future projects suggests that investors are looking beyond the current earnings results.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | -108.62% |
| Revenue | N/A | N/A | N/A |
Management remains focused on long-term growth and innovation. They acknowledged the challenges in the current quarter but emphasized their commitment to advancing their projects.
Management highlighted ongoing research and development efforts.
They expressed confidence in future product pipelines despite current EPS results.